

CHANGE OF AUDITOR

MELBOURNE (AUSTRALIA) 16 January 2024: Invion Limited (ASX: IVX) ("Invion" or the "Company") is pleased to announce the appointment of William Buck Audit (Vic) Pty Ltd as its auditor to replace Grant Thornton.

The decision to change auditor has been approved by Invion's Board of Directors as it is in the best interests of shareholders.

Grant Thornton applied for consent to resign as the auditor of Invion Limited and this consent was subsequently approved by ASIC. The Company appreciates the work of its outgoing auditor, Grant Thornton, and looks forward to working with William Buck Audit (Vic) Pty Ltd.

This announcement was approved for release by Invion's Board of Directors.

Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea to the Photosoft™ technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). INV043 is a novel, patent protected photosensitiser which in conjunction with light and oxygen, selectively kills cancer cells and promotes an immune response with the potential to attack other related cancers. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.